{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"95"},{"groupId":"OG005","value":"5"}],"units":"Participants"}],"description":"Overall response rate was assessed according to Immune-related Response Criteria (irRC) (Wolchok, Hoos et al. 2009). ORR is the number of participants with a best overall response of Immune-related Complete Response (irCR) or Immune-related Partial Response (irPR).\n\nirCR is defined as complete disappearance of all lesions with no new lesions; irPR as a ≥50% decrease in tumor burden from baseline; both are confirmed ≥4 weeks after initial documentation.\n\nOnly participants with adequate irRC tumor assessments (baseline and ≥1 post-baseline) and without major protocol deviations, were included in the analysis.","groups":[{"description":"Participants received 0.08 or 0.1 mg of Pegilodecakin once daily (QD) administered subcutaneously (SC).\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG000","title":"Part A: Pegilodecakin 0.08/0.1 mg"},{"description":"Participants received 0.2 or 0.25 mg of Pegilodecakin QD administered SC. Study treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG001","title":"Part A: Pegilodecakin 0.2/0.25 mg"},{"description":"Participants received 0.4 or 0.5 mg of Pegilodecakin QD administered SC. Study treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG002","title":"Part A: Pegilodecakin 0.4/0.5 mg"},{"description":"Participants received 0.8 or 1 mg of Pegilodecakin QD administered SC. Study treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG003","title":"Part A: Pegilodecakin 0.8/1 mg"},{"description":"Participants received 1.6 or 2 mg of Pegilodecakin QD administered SC. Study treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG004","title":"Part A: Pegilodecakin 1.6/2 mg"},{"description":"Participants received 3.2 or 4 mg of Pegilodecakin QD administered SC. Study treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"OG005","title":"Part A: Pegilodecakin 3.2/4 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants who received at least one dose of study intervention(s) and had an adequate irRC tumor assessment were included in the analysis.","reportingStatus":"POSTED","timeFrame":"From Date of First Dose of study drug until Disease Progression or Death (Up to 54 months)","title":"Part A: Number of Participants With Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Participants"}